Nebulized Azithromycin as an Adjuvant Preventive Therapy for Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial

Journal of Clinical Neonatology 2026 Open access

Read full text
Authors: Marwa Mohamed Farag, Hesham Abd El –Rahim Ghazal, Mohamed Hazem Gouda, Ahmed Abd El-Halim Abd El-Raziq Khedr
DOI: 10.4103/jcn.jcn_91_25
Cited by: 0
References: 24

Abstract

Context: Azithromycin (AZM) is a promising anti-inflammatory medication that may mitigate bronchopulmonary dysplasia (BPD) in very preterm newborns. Aim: The objectives were to assess the effectiveness and safety of AZM in BPD prevention in preterm neonates. Settings and Design: Prospective randomized-controlled-trial conducted at the Neonatal-Intensive-Care Unit of Alexandria-University-Maternity-Hospital from November 2024 to May 2025. Methods: A total of 100 neonates with gestational age

Fields of Study & Subjects

Neonatal Respiratory Health Research Preterm Birth and Chorioamnionitis Neonatal and fetal brain pathology

Publication details

Journal / source
Journal of Clinical Neonatology
Volume
15
Issue
1
Pages
7–15
Publication date
1 January 2026
Language
EN